SAINT BELLA GP Delivers 36% Revenue Growth and 56% Surge in Adjusted Net Profit in 1H 2026

Bulletin Express21:23

SAINT BELLA GP reported a robust top-line performance for the six months ended 30 June 2026, with revenue climbing 36.0% year on year to RMB 611.41 million. Growth was broad-based across its core postpartum care, home-care services and female health-nourishment segments, supported by continued network expansion and acquisitions.

• Financial overview – Revenue: RMB 611.41 million (1H 2025: RMB 449.51 million). – Gross profit: RMB 221.22 million, up 30.8%; gross margin eased 1.4 pp to 36.2% as new and acquired centres diluted profitability during ramp-up. – Net profit: RMB 53.97 million versus RMB 326.90 million a year earlier, reflecting the absence of a one-off RMB 318.20 million fair-value gain booked in 1H 2025. – Adjusted net profit (non-HKFRS): RMB 60.58 million, up 56.2%, lifting the adjusted net margin to 9.9% (1H 2025: 8.6%). – Basic EPS: RMB 0.08 (1H 2025: RMB 17.31). – Operating cash flow: RMB 87.33 million; cash and cash equivalents stood at RMB 392.08 million at period-end (31 Dec 2025: RMB 549.65 million).

• Segment highlights 1. Postpartum care revenue rose 31.4% to RMB 508.00 million. Average selling price across the “Saint Bella”, “Bella Isla” and “Baby Bella” brands increased 15.9% to RMB 171,011. The network expanded to 148 global outlets, aided by the strategic acquisition of Wuhan-based “Fu Lei Ya”. 2. Home-care services grew 59.1% to RMB 61.40 million, driven by upgraded age-specific childcare offerings; the specialist pool expanded to 11,495 professionals. 3. Female health-nourishment sales advanced 44.4% to RMB 35.10 million, buoyed by strong demand for core “Yue Zhi Jing Hua” products and new “Yue Zhi Cha Yin” lines. 4. AI intelligent-agent services generated inaugural revenue of RMB 6.90 million, as the proprietary “Dr. Bella” platform was deployed in 207 stores.

• Cost management and margins Marketing and administrative expense ratios declined by 0.7 pp and 5.4 pp respectively, reflecting scale benefits and technology-driven efficiencies. Research and development spending edged up 9.1% to RMB 6.19 million.

• Balance sheet and capital allocation Total assets less current liabilities reached RMB 1.13 billion. Interest-bearing bank borrowings increased to RMB 93.50 million, while lease liabilities stood at RMB 176.25 million. The interest-bearing debt ratio was 5.4%. From the HK$709.10 million IPO proceeds (including HK$79.13 million from the over-allotment), HK$86.90 million was deployed in 1H 2026, leaving HK$509.20 million earmarked mainly for network expansion, new services, talent development, R&D and working capital. No interim dividend was declared.

• Outlook and strategy Management reiterated its goal of becoming a leading global home-care brand group. Priorities for 2H 2026 include continued dual-track growth (organic openings and targeted M&A), launch of a flagship full-cycle women’s-care hub in Beijing, further overseas roll-outs in cities such as London and Sydney, and broader commercialisation of the “AI + Care” platform.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment